Dulaglutide vs Orforglipron
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Trulicity
An FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.
Also: LY3502970, OWL833
An oral non-peptide GLP-1 receptor agonist. FDA approved April 1, 2026 under the brand name Foundayo — the first daily oral GLP-1 pill for weight loss. Distribution began April 6, 2026. FDA subsequently requested additional post-approval safety data.
Key Comparison Insights
- Both Dulaglutide and Orforglipron are FDA approved medications.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Dulaglutide has stronger research evidence (FDA Approved) compared to Orforglipron (Human Trials).
Detailed Comparison
| Attribute | Dulaglutide | Orforglipron |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Dulaglutide consists of two GLP-1 analogs linked to a modified human IgG4 Fc fragment. This structure extends half-life to about 5 days, allowing weekly dosing. Works through standard GLP-1 receptor activation. | Orforglipron is a small molecule that activates GLP-1 receptors similarly to peptide GLP-1 agonists. Being a non-peptide allows oral bioavailability without the special formulation needed for oral semaglutide. |
| Common Dosing | 1.5-4.5 mg weekly Once weekly | Limited community data available See research protocols |
| Administration | Subcutaneous injection weekly | Oral tablet daily |
| Typical Duration | Long-term / chronic use | Long-term use expected |
| Best Time to Take | Before bed or morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | AWARD program showed significant A1C reduction and weight loss. REWIND trial demonstrated cardiovascular benefits in broader diabetic population. Generally shows 3-5% weight loss in trials. | ATTAIN-1 Phase 3 results showed significant weight loss. ATTAIN-MAINTAIN showed it helps maintain weight after injectable GLP-1 treatment. NDA submitted late 2025. Selected for FDA National Priority Voucher program but review was delayed to April 2026. FDA approved Foundayo (orforglipron) on April 1, 2026 under the National Priority Voucher Program — the fastest new molecular entity approval since 2002. It is the first oral non-peptide GLP-1 receptor agonist approved for chronic weight management. |
Frequently Asked Questions: Dulaglutide vs Orforglipron
What is the difference between Dulaglutide and Orforglipron?
Dulaglutide is a weight loss peptide that an fda-approved weekly glp-1 receptor agonist for type 2 diabetes. fused to an fc antibody fragment for extended duration of action. Orforglipron is a weight loss peptide that an oral non-peptide glp-1 receptor agonist. fda approved april 1, 2026 under the brand name foundayo — the first daily oral glp-1 pill for weight loss. distribution began april 6, 2026. fda subsequently requested additional post-approval safety data. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Dulaglutide or Orforglipron?
Neither is universally "better" - the choice depends on your specific goals. Dulaglutide is typically used for weight loss purposes, while Orforglipron is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Dulaglutide and Orforglipron be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Dulaglutide and Orforglipron together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.